Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX-101 vs Povidone-Iodine for Ocular Sterilization (CLEAN)
NCT05127525Phase 3Terminated
- Sponsor
- iRenix Medical, Inc.
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of IRX-101 in infectious endophthalmitis (2 arms), sponsored by iRenix Medical, Inc. Primary endpoint: Incidence of infectious endophthalmitis after topical use of IRX-101 combined with IVT at 2 hours. Started Nov 2021; status: terminated.
02
Drugs
IRX-101
03
Conditions
infectious endophthalmitis
Beyond the preview
Go deeper on NCT05127525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127525.